Clinical Trial Update: Dose Escalation of Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) [Phase 2]

View source ↗

Summary

This update reports results from a Phase 2 dose-escalation study of Sorafenib in patients with advanced hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Sorafenib (Sorafenib)

Snippet

Sponsor: Istituto Clinico Humanitas | Conditions: Carcinoma, Hepatocellular | Phase 2 | Status: COMPLETED